What clinicians need to know about intranasal esketamine for treatment-resistant depression?
Australasian Psychiatry November 14, 2023 Judith D. Hope, David Copolov, John Tiller et al.
Objective To review the usefulness of esketamine for treatment-resistant depression. Method Pivotal trials of intranasal esketamine in treatment-resistant depression were synthesized as a narrative review. Results Esketamine is postulated to act through antagonism of N-methyl-D-aspartate (NMDA) glutamate receptors, but opioidergic effects may also be involved. Unlike intravenous ketamine,...